Genetic Aspects of Porphyria Cutanea Tarda

Richard W. Lambrecht; Manish Thapar; Herbert L. Bonkovsky

doi:10.1055/s-2006-960173

Seminars in Liver Disease, Table of Contents

Semin Liver Dis 2007; 27(1): 099-108
DOI: 10.1055/s-2006-960173

Genetic Aspects of Porphyria Cutanea Tarda

Richard W. Lambrecht¹ , Manish Thapar² , Herbert L. Bonkovsky³

¹Department of Pharmacology, and The Liver-Biliary-Pancreatic Center, University of Connecticut Health Center, Farmington, Connecticut
²Department of Medicine, University of Connecticut Health Center, Farmington, Connecticut
³Departments of Medicine and Molecular, Microbial, & Structural Biology, and The Liver-Biliary-Pancreatic Center, University of Connecticut Health Center, Farmington, Connecticut

Abstract

ABSTRACT

Porphyria cutanea tarda (PCT) is caused by disruption of heme biosynthesis at the step catalyzed by uroporphyrinogen decarboxylase. The patients present with photosensitive cutaneous lesions, hepatic pathology (including elevated porphyrin levels), and increased excretion of porphyrins. Therapy consists of removing the exacerbating factors of PCT (reduced sunlight exposure, abstinence from alcohol use, decreased estrogen exposure, and treatment for viral infections), decreasing body iron stores (by therapeutic phlebotomy or by the use of the new orally active iron chelators), and, in some instances, the use of low-dose antimalarials. Recent advances in genetics and genomics have allowed DNA testing for porphyria cutanea tarda and are likely to be instrumental in developing improved, gene-based treatments and in finding genetic loci (in addition to uroporphyrinogen decarboxylase) involved in the clinical expression of this disease.

KEYWORDS

Porphyria cutanea tarda - heme biosynthesis - genetics - genomics

Full Text

References

REFERENCES

1 Waldenstrom J. Studien ueber Porphyrie. Acta Med Scand. 1937; 82(suppl) 1-254
2 Elder G H. Porphyria cutanea tarda. Semin Liver Dis. 1998; 18 67-75
3 Sweeney G D. Porphyria cutanea tarda, or the uroporphyrinogen decarboxylase deficiency diseases. Clin Biochem. 1986; 19 3-15
4 Moran M J, Fontanellas A, Brudieux E et al.. Hepatic uroporphyrinogen decarboxylase activity in porphyria cutanea tarda patients: the influence of virus C infection. Hepatology. 1998; 27 584-589
5 Elder G H. The cutaneous porphyrias. Semin Dermatol. 1990; 9 63-69
6 O'Reilly F M, Darby C, Fogarty J et al.. Screening of patients with iron overload to identify hemochromatosis and porphyria cutanea tarda. Arch Dermatol. 1997; 133 1098-1101
7 Bonkovsky H L, Lambrecht R W, Shan Y. Iron as a co-morbid factor in nonhemochromatotic liver disease. Alcohol. 2003; 30 137-144
8 Bonkovsky H L, Lambrecht R W. Iron-induced liver injury. Clin Liver Dis. 2000; 4 409-429
9 Alla V, Bonkovsky H L. Iron in nonhemochromatotic liver disorders. Semin Liver Dis. 2005; 25 461-472
10 Felsher B F, Kushner J P. Hepatic siderosis and porphyria cutanea tarda: relation of iron excess to the metabolic defect. Semin Hematol. 1977; 14 243-251
11 Lambrecht R W, Jacobs J M, Sinclair P R, Sinclair J F. Inhibition of uroporphyrinogen decarboxylase activity: the role of cytochrome P-450-mediated uroporphyrinogen oxidation. Biochem J. 1990; 269 437-441
12 Lambrecht R W, Bonkovsky H L. Hemochromatosis and porphyria. Semin Gastrointest Dis. 2002; 13 109-119
13 Mukerji S K. Haem biosynthesis and human porphyria cutanea tarda: effects of alcohol intake. Indian J Exp Biol. 2000; 38 635-642
14 Daniell W E, Stockbridge H L, Labbe R F et al.. Environmental chemical exposures and disturbances of heme synthesis. Environ Health Perspect. 1997; 105(suppl 1) 37-53
15 Mor Z, Caspi E. Cutaneous complications of hormonal replacement therapy. Clin Dermatol. 1997; 15 147-154
16 Sterling R K, Bralow S. Extrahepatic manifestations of hepatitis C virus. Curr Gastroenterol Rep. 2006; 8 53-59
17 Almehmi A, Deliri H, Szego G G et al.. Porphyria cutanea tarda in a patient with HIV-infection. W V Med J. 2005; 101 19-21
18 Bonkovsky H L, Poh-Fitzpatrick M, Pimstone N et al.. Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America. Hepatology. 1998; 27 1661-1669
19 Kondo M, Yano Y, Shirataka M, Urata G, Sassa S. Porphyrias in Japan: compilation of all cases reported through 2002. Int J Hematol. 2004; 79 448-456
20 Badminton M N, Elder G H. Molecular mechanisms of dominant expression in porphyria. J Inherit Metab Dis. 2005; 28 277-286
21 Elder G H, Urquhart A J, De Salamanca R E, Munoz J J, Bonkovsky H L. Immunoreactive uroporphyrinogen decarboxylase in the liver in porphyria cutanea tarda. Lancet. 1985; 2 229-233
22 Egger N G, Goeger D E, Payne D A et al.. Porphyria cutanea tarda: multiplicity of risk factors including HFE mutations, hepatitis C, and inherited uroporphyrinogen decarboxylase deficiency. Dig Dis Sci. 2002; 47 419-426
23 Armstrong D K, Sharpe P C, Chambers C R et al.. Hepatoerythropoietic porphyria: a missense mutation in the UROD gene is associated with mild disease and an unusual porphyrin excretion pattern. Br J Dermatol. 2004; 151 920-923
24 Elder G H, Smith S G, Herrero C et al.. Hepatoerythropoietic porphyria: a new uroporphyrinogen decarboxylase defect or homozygous porphyria cutanea tarda?. Lancet. 1981; 1 916-919
25 Cruz-Rojo J, Fontanellas A, Moran-Jimenez M J et al.. Precipitating/aggravating factors of porphyria cutanea tarda in Spanish patients. Cell Mol Biol (Noisy-le-grand). 2002; 48 845-852
26 Pimstone N R. Hematologic and hepatic manifestations of the cutaneous porphyrias. Clin Dermatol. 1985; 3 83-102
27 Bonkovsky H L. Mechanism of iron potentiation of hepatic uroporphyria: studies in cultured chick embryo liver cells. Hepatology. 1989; 10 354-364
28 Fracanzani A L, Taioli E, Sampietro M et al.. Liver cancer risk is increased in patients with porphyria cutanea tarda in comparison to matched control patients with chronic liver disease. J Hepatol. 2001; 35 498-503
29 Shehan J M, Huerter C J. Porphyria cutanea tarda associated with an acute gastrointestinal bleed: the roles of supplemental iron and blood transfusion. Cutis. 2001; 68 147-150
30 Chemmanur A T, Bonkovsky H L. Hepatic porphyrias: diagnosis and management. Clin Liver Dis. 2004; 8 807-838
31 Badiu C, Cristofor D, Voicu D, Coculescu M. Diagnostic traps in porphyria: case report and literature review. Rev Med Chir Soc Med Nat Iasi. 2004; 108 584-591
32 Lockwood W H, Poulos V, Rossi E, Curnow D H. Rapid procedure for fecal porphyrin assay. Clin Chem. 1985; 31 1163-1167
33 Cooper C L, Stob C M, Jones M A, Lash T D. Metabolism of pentacarboxylate porphyrinogens by highly purified human coproporphyrinogen oxidase: further evidence for the existence of an abnormal pathway for heme biosynthesis. Bioorg Med Chem. 2005; 13 6244-6251
34 Lim C K, Peters T J. Urine and faecal porphyrin profiles by reversed-phase high-performance liquid chromatography in the porphyrias. Clin Chim Acta. 1984; 139 55-63
35 Kostler E, Wollina U. Therapy of porphyria cutanea tarda. Expert Opin Pharmacother. 2005; 6 377-383
36 Freesemann A, Frank M, Sieg I, Doss M O. Treatment of porphyria cutanea tarda by the effect of chloroquine on the liver. Skin Pharmacol. 1995; 8 156-161
37 Drago F, Battifoglio M L, Gelati G, Rebora A. Very low-dose chloroquine treatment for porphyria cutanea tarda. Acta Derm Venereol. 1995; 75 329-330
38 Berk D R, Mallory S B, Keeffe E B, Ahmed A. Dermatologic disorders associated with chronic hepatitis C: effect of interferon therapy. Clin Gastroenterol Hepatol. 2006; , August 16 (Epub ahead of print)
39 Hift R J, Corrigall A V, Hancock V et al.. Porphyria cutanea tarda: the etiological importance of mutations in the HFE gene and viral infection is population-dependent. Cell Mol Biol (Noisy-le-grand). 2002; 48 853-859
40 Ajioka R S, Phillips J D, Kushner J P. Biosynthesis of heme in mammals. Biochim Biophys Acta. 2006; 1763 723-736
41 Ponka P. Cell biology of heme. Am J Med Sci. 1999; 318 241-256
42 Tsiftsoglou A S, Tsamadou A I, Papadopoulou L C. Heme as key regulator of major mammalian cellular functions: molecular, cellular, and pharmacological aspects. Pharmacol Ther. 2006; 111 327-345
43 Ibraham N G, Friedland M L, Levere R D. Heme metabolism in erythroid and hepatic cells. Prog Hematol. 1983; 13 75-130
44 Taketani S. Acquisition, mobilization and utilization of cellular iron and heme: endless findings and growing evidence of tight regulation. Tohoku J Exp Med. 2005; 205 297-318
45 Podvinec M, Handschin C, Looser R, Meyer U A. Identification of the xenosensors regulating human 5-aminolevulinate synthase. Proc Natl Acad Sci USA. 2004; 101 9127-9132
46 Surinya K H, Cox T C, May B K. Transcriptional regulation of the human erythroid 5-aminolevulinate synthase gene: identification of promoter elements and role of regulatory proteins. J Biol Chem. 1997; 272 26585-26594
47 Munakata H, Sun J Y, Yoshida K et al.. Role of the heme regulatory motif in the heme-mediated inhibition of mitochondrial import of 5-aminolevulinate synthase. J Biochem (Tokyo). 2004; 136 233-238
48 Cable E E, Gildemeister O S, Pepe J A et al.. Hepatic 5-aminolevulinic acid synthase mRNA stability is modulated by inhibitors of heme biosynthesis and by metalloporphyrins. Eur J Biochem. 1996; 240 112-117
49 Kolluri S, Sadlon T J, May B K, Bonkovsky H L. Haem repression of the housekeeping 5-aminolaevulinic acid synthase gene in the hepatoma cell line LMH. Biochem J. 2005; 392 173-180
50 Lincoln B C, Aw T Y, Bonkovsky H L. Heme catabolism in cultured hepatocytes: evidence that heme oxygenase is the predominant pathway and that a proportion of synthesized heme is converted rapidly to biliverdin. Biochim Biophys Acta. 1989; 992 49-58
51 Maines M D, Trakshel G M, Kutty R K. Characterization of two constitutive forms of rat liver microsomal heme oxygenase: only one molecular species of the enzyme is inducible. J Biol Chem. 1986; 261 411-419
52 Sun J, Hoshino H, Takaku K et al.. Hemoprotein Bach1 regulates enhancer availability of heme oxygenase-1 gene. EMBO J. 2002; 21 5216-5224
53 Sun J, Brand M, Zenke Y et al.. Heme regulates the dynamic exchange of Bach1 and NF-E2-related factors in the Maf transcription factor network. Proc Natl Acad Sci USA. 2004; 101 1461-1466
54 Shan Y, Lambrecht R W, Ghaziani T, Donohue S E, Bonkovsky H L. Role of Bach-1 in regulation of heme oxygenase-1 in human liver cells: insights from studies with small interfering RNAS. J Biol Chem. 2004; 279 51769-51774
55 Shan Y, Lambrecht R W, Bonkovsky H L. Identification of key elements that are responsible for heme-mediated induction of the avian heme oxygenase-1 gene. Biochim Biophys Acta. 2004; 1679 87-94
56 Wijayanti N, Katz N, Immenschuh S. Biology of heme in health and disease. Curr Med Chem. 2004; 11 981-986
57 Phillips J D, Jackson L K, Bunting M et al.. A mouse model of familial porphyria cutanea tarda. Proc Natl Acad Sci USA. 2001; 98 259-264
58 Rao A U, Carta L K, Lesuisse E, Hamza I. Lack of heme synthesis in a free-living eukaryote. Proc Natl Acad Sci USA. 2005; 102 4270-4275
59 Rothstein M, Coppens M. Nutritional factors and conditions for the axenic culture of free-living nematodes. Comp Biochem Physiol B. 1978; 61 99-104
60 Whitby F G, Phillips J D, Kushner J P, Hill C P. Crystal structure of human uroporphyrinogen decarboxylase. EMBO J. 1998; 17 2463-2471
61 Martins B M, Grimm B, Mock H P, Huber R, Messerschmidt A. Crystal structure and substrate binding modeling of the uroporphyrinogen-III decarboxylase from Nicotiana tabacum: implications for the catalytic mechanism. J Biol Chem. 2001; 276 44108-44116
62 Romana M, Le Boulch P, Romeo P H. Rat uroporphyrinogen decarboxylase cDNA: nucleotide sequence and comparison to human uroporphyrinogen decarboxylase. Nucleic Acids Res. 1987; 15 7211
63 Phillips J D, Parker T L, Schubert H L et al.. Functional consequences of naturally occurring mutations in human uroporphyrinogen decarboxylase. Blood. 2001; 98 3179-3185
64 Smith A G, Francis J E. Investigations of rat liver uroporphyrinogen decarboxylase: comparisons of porphyrinogens I and III as substrates and the inhibition by porphyrins. Biochem J. 1981; 195 241-250
65 Sinclair P, Lambrecht R, Sinclair J. Evidence for cytochrome P450-mediated oxidation of uroporphyrinogen by cell-free liver extracts from chick embryos treated with 3-methylcholanthrene. Biochem Biophys Res Commun. 1987; 146 1324-1329
66 Jacobs J M, Sinclair P R, Bement W J et al.. Oxidation of uroporphyrinogen by methylcholanthrene-induced cytochrome P-450: essential role of cytochrome P-450d. Biochem J. 1989; 258 247-253
67 Jacobs J M, Sinclair P R, Lambrecht R W, Sinclair J F, Jacobs N J. Role of inducer binding in cytochrome P-450 IA2-mediated uroporphyrinogen oxidation. J Biochem Toxicol. 1990; 5 193-199
68 Romana M, Dubart A, Beaupain D et al.. Structure of the gene for human uroporphyrinogen decarboxylase. Nucleic Acids Res. 1987; 15 7343-7356
69 Hansen J L, Pryor M A, Kennedy J B, Kushner J P. Steady-state levels of uroporphyrinogen decarboxylase mRNA in lymphoblastoid cell lines from patients with familial porphyria cutanea tarda and their relatives. Am J Hum Genet. 1988; 42 847-853
70 Harraway J R, Florkowski C M, Sies C, George P M. Dual porphyria with mutations in both the UROD and HMBS genes. Ann Clin Biochem. 2006; 43 80-82
71 Christiansen L, Brons-Poulsen J, Horder M, Brock A, Petersen N E. Expression and characterization of six clinically relevant uroporphyrinogen decarboxylase gene mutations. Scand J Clin Lab Invest. 2005; 65 227-235
72 Mendez M, Rossetti M V, Del C Batlle A M, Parera V E. The role of inherited and acquired factors in the development of porphyria cutanea tarda in the Argentinean population. J Am Acad Dermatol. 2005; 52 417-424
73 Poblete-Gutierrez P, Mendez M, Wiederholt T et al.. The molecular basis of porphyria cutanea tarda in Chile: identification and functional characterization of mutations in the uroporphyrinogen decarboxylase gene. Exp Dermatol. 2004; 13 372-379
74 Martinez di Montemuros F, Tavazzi D, Patti E, Cappellini M D. Human gene mutations. Gene symbol: UROD. Disease: porphyria, cutanea tarda. Hum Genet. 2004; 114 221
75 Martinez di Montemuros F, Tavazzi D, Patti E, Cappellini M D. Gene symbol: UROD. Disease: porphyria, cutanea tarda. Hum Genet. 2003; 113 368
76 Martinez di Montemuros F, Di Pierro E, Patti E et al.. Molecular characterization of porphyrias in Italy: a diagnostic flow-chart. Cell Mol Biol (Noisy-le-grand). 2002; 48 867-876
77 Ged C, Ozalla D, Herrero C et al.. Description of a new mutation in hepatoerythropoietic porphyria and prenatal exclusion of a homozygous fetus. Arch Dermatol. 2002; 138 957-960
78 Cappellini M D, Martinez di Montemuros F, Tavazzi D et al.. Seven novel point mutations in the uroporphyrinogen decarboxylase (UROD) gene in patients with familial porphyria cutanea tarda (f-PCT). Hum Mutat. 2001; 17 350
79 Christiansen L, Ged C, Hombrados I et al.. Screening for mutations in the uroporphyrinogen decarboxylase gene using denaturing gradient gel electrophoresis: identification and characterization of six novel mutations associated with familial PCT. Hum Mutat. 1999; 14 222-232
80 McManus J F, Begley C G, Sassa S, Ratnaike S. Three new mutations in the uroporphyrinogen decarboxylase gene in familial porphyria cutanea tarda: mutation in brief no. 237. Online. Hum Mutat. 1999; 13 412
81 McManus J F, Begley C G, Sassa S, Ratnaike S. Five new mutations in the uroporphyrinogen decarboxylase gene identified in families with cutaneous porphyria. Blood. 1996; 88 3589-3600
82 Garey J R, Hansen J L, Harrison L M, Kennedy J B, Kushner J P. A point mutation in the coding region of uroporphyrinogen decarboxylase associated with familial porphyria cutanea tarda. Blood. 1989; 73 892-895
83 Garey J R, Harrison L M, Franklin K F et al.. Uroporphyrinogen decarboxylase: a splice site mutation causes the deletion of exon 6 in multiple families with porphyria cutanea tarda. J Clin Invest. 1990; 86 1416-1422
84 Peters H A, Cripps D J, Lambrecht R W et al.. History and geography of hexachlorobenzene poisoning in southeastern Turkey. IARC Sci Publ. 1986; (77) 131-132
85 Erturk E, Lambrecht R W, Peters H A et al.. Oncogenicity of hexachlorobenzene. IARC Sci Publ. 1986; (77) 417-423
86 Lambrecht R W, Sinclair P R, Bement W J, Sinclair J F. Uroporphyrin accumulation in cultured chick embryo hepatocytes: comparison of 2,3,7,8-tetrachlorodibenzo-p-dioxin and 3,4,3′,4′-tetrachlorobiphenyl. Toxicol Appl Pharmacol. 1988; 96 507-516
87 Gorman N, Ross K L, Walton H S et al.. Uroporphyria in mice: thresholds for hepatic CYP1A2 and iron. Hepatology. 2002; 35 912-921
88 Lambrecht R W, Sinclair P R, Bement W J et al.. Hepatic uroporphyrin accumulation and uroporphyrinogen decarboxylase activity in cultured chick-embryo hepatocytes and in Japanese quail (Coturnix coturnix japonica) and mice treated with polyhalogenated aromatic compounds. Biochem J. 1988; 253 131-138
89 Cantoni L, Graziani A, Rizzardini M, Saletti M C. Porphyrinogenic effect of hexachlorobenzene and 2,3,7,8-tetrachlorodibenzo-para-dioxin: is an inhibitor involved in uroporphyrinogen decarboxylase inactivation?. IARC Sci Publ. 1986; (77) 449-456
90 Goldstein J A, Friesen M, Scotti T M et al.. Assessment of the contribution of chlorinated dibenzo-p-dioxins and dibenzofurans to hexachlorobenzene-induced toxicity, porphyria, changes in mixed function oxygenases, and histopathological changes. Toxicol Appl Pharmacol. 1978; 46 633-649
91 Bowers M A, Luckhurst C L, Davis H A, Woods J S. Investigation of factors influencing urinary porphyrin excretion in rats: strain, gender, and age. Fundam Appl Toxicol. 1992; 19 538-544
92 Wang H, Long Q, Marty S D, Sassa S, Lin S. A zebrafish model for hepatoerythropoietic porphyria. Nat Genet. 1998; 20 239-243
93 Cappellini M D. Iron-chelating therapy with the new oral agent ICL670 (Exjade). Best Pract Res Clin Haematol. 2005; 18 289-298
94 Vanorden H E, Hagemann T M. Deferasirox: an oral agent for chronic iron overload. Ann Pharmacother. 2006; 40 1110-1117
95 Fontanellas A, Mazurier F, Moreau-Gaudry F et al.. Correction of uroporphyrinogen decarboxylase deficiency (hepatoerythropoietic porphyria) in Epstein-Barr virus-transformed B-cell lines by retrovirus-mediated gene transfer: fluorescence-based selection of transduced cells. Blood. 1999; 94 465-474
96 Richard E, Geronimi F, Lalanne M et al.. A bicistronic SIN-lentiviral vector containing G156A MGMT allows selection and metabolic correction of hematopoietic protoporphyric cell lines. J Gene Med. 2003; 5 737-747

Richard W LambrechtPh.D.

Assistant Professor, Department of Pharmacology, and The Liver-Biliary-Pancreatic Center, University of Connecticut Health Center

263 Farmington Avenue, Farmington, CT 06030-1119